X
[{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kimia Therapeutics Raises $55 Million Series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Kimia Therapeutics
Filters
Companies By Therapeutic Area
Details:
The net proceeds will enable Kimia to expand its ATLAS platform and pursue a broad range of therapeutic targets in oncology, immunology and inflammation.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
The Column Group
Deal Size: $55.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
December 19, 2023
Details:
The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Lead Product(s):
CT-388
Therapeutic Area: Endocrinology
Product Name: CT-388
Highest Development Status: Phase I
Product Type: Peptide
Partner/Sponsor/Collaborator:
Carmot Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Demerger
January 05, 2023